Navigation Links
Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
Date:3/16/2009

urgery. Previous meetings with FDA have indicated that no other clinical trials are necessary for NDA approval and so we are eagerly awaiting the results of both trials in anticipation of our NDA filing and future commercial launch of the product in the U.S."

About Gentamicin Surgical Implant

GENTAMICIN SURGICAL IMPLANT is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) directly to the target tissue for localized action, while maintaining low systemic levels well below the toxicity threshold. The product was developed using Innocoll's proprietary collagen-based drug delivery technology, CollaRx, and (outside of the U.S.) is indicated as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues. GENTAMICIN SURGICAL IMPLANT is already approved in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and there are more than 60 prospective clinical trials and published case reports totaling over 7,500 patients documenting its safety and efficacy over a broad range of orthopedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures. The product is in phase 3 clinical trials in the U.S. for the prevention of surgical site infections and has received FDA fast-track designation for this indication.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll has licensed its US marketing
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
4. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
9. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
10. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
11. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Reportlinker.com announces that a new market ... Global Heart Valve Repair and Replacement Market ... About Heart Valve Repair and Replacement Heart ... control the flow of blood during the cardiac ... such as valvular stenosis, valvular insufficiency or regurgitation, ...
(Date:8/27/2014)... -- Reportlinker.com announces that a new market research report ... Eastern Europe 2014 http://www.reportlinker.com/p02312454/Baby-Food-Eastern-Europe-2014.html ... a new report by ERC that analyzes the Baby ... , key segments, features & developments, future projections ... which are currently affecting the industry. Furthermore, it profiles ...
(Date:8/27/2014)... Aug. 27, 2014 North American lighting leader ... 100 Award for the new OSRAM ITOS ® PHASER ... light module for microscopy, endoscopy and surgical head lamps that ... higher efficacy and lamp life. "We,re honored to ... the most innovative new technologies of the past year," said ...
Breaking Medicine Technology:Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
... , BASKING RIDGE, N.J., Nov. 11 Regado ... of antithrombotic aptamers with active control agents, announced ... Chief Scientific Officer, will be presenting an abstract ... Center in Philadelphia, Pennsylvania. Dr. Rusconi,s abstract "Aptamer-Active ...
... Recap LLC (Recap) has launched "Development Optimizer," the ... Deloitte. The series of biopharmaceutical business intelligence tools ... toward business development, corporate strategy, financial, clinical development, ... Optimizer" provides flexible analytical tools for biopharmaceutical executives ...
Cached Medicine Technology:Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009 2Deloitte Recap Launches New Solution for Clinical Development 2Deloitte Recap Launches New Solution for Clinical Development 3
(Date:8/27/2014)... CO (PRWEB) August 27, 2014 For ... to performances by the beloved mantra singers Deva Premal ... Following the release of their latest album in ... touching down in twenty-two countries around the globe, including ... Chile, Argentina and across Europe. With a new album ...
(Date:8/27/2014)... 27, 2014 BESLER Consulting , ... services for hospitals, is pleased to announce that it ... of America’s Fastest-Growing Companies. The list represents the most ... independent entrepreneurs. , "It's been an exciting year ... included in this year's Inc. 5000 list,” said Jonathan ...
(Date:8/27/2014)... AZ (PRWEB) August 27, 2014 ... of in-home care for seniors, is proud to announce ... Series. The upcoming webinar will feature Dr. Suzanne Steinbaum, ... Lenox Hill Hospital in New York City, National Spokesperson ... author. The webinar will cover the issues surrounding women ...
(Date:8/27/2014)... new analysis of clinical trial participation in the largest ... found participants are not representative of the larger patient ... Hospital cardiologist Dr. Jay Udell. The study authors call ... the wider population, and suggest the use of broader ... participation. , "We know that clinical trials can be ...
(Date:8/27/2014)... researchers developed and tested an advanced statistical model ... contribute to disease as published yesterday in ... fills a gap in current analyses. Complex diseases ... genetic and environmental factors. When many such combinations ... that reflect chance combinations among affected individuals becomes ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... by a specialty pharmacy program were more compliant with ... for their disease than those who were not managed ... completed by HealthCore, Inc. , HealthCore researcher Jingbo Yu ... Pharmacoeconomic and Outcomes Research 14th Annual International Meeting in ...
... RECORDING OF DAVID COOK,S ,IDOL, PERFORMANCE WILL BE SOLD ... Sale of Live Version of ,Permanent, Will Be Donated ... Exactly one year after winning the seventh season ... popular television series in America on Wednesday night to ...
... the 80th anniversary of The Children,s Center of Wayne ... a Power of Possibilities Breakfast is being held on ... http://www.newscom.com/cgi-bin/prnh/20090423/CCWCLOGO ) Embarking on its ... of founder Senator James Couzens. His intention was ...
... NAPERVILLE, Ill., May 20 Viant, Inc., a leader ... that they have signed an agreement with Tempe, AZ-based ... in the state of Arizona. Viant customers utilizing the ... have access to HMA, Inc.,s Arizona provider networks, which ...
... in Texas. , ... Houston, TX (PRWEB) May ... leading provider of retirement services in the academic, medical research and ... the 2009 TIAA-CREF Distinguished Medical Educator Award ( www.tiaa-crefaward.org ...
... Depression Are Diagnosed by a Physician - Dramatically ... SymptomsORLANDO, Fla., May 20 Whites experiencing depression ... a physician than other ethnic groups, according to ... today at the 14th Annual ISPOR (International Society ...
Cached Medicine News:Health News:MS patients more compliant with medications when managed by specialty pharmacy 2Health News:David Cook to Perform 'Permanent' on the American Idol Season Finale Tonight 2Health News:80th Anniversary Power of Possibilities Breakfast Honors the Children's Center of Wayne County 2Health News:Viant Expands Relationship With HMA for Improved Healthcare Access in AZ 2Health News:Open Call for Nominations for the Sixth Annual TIAA-CREF Distinguished Medical Educator Award 2Health News:Open Call for Nominations for the Sixth Annual TIAA-CREF Distinguished Medical Educator Award 3Health News:Open Call for Nominations for the Sixth Annual TIAA-CREF Distinguished Medical Educator Award 4Health News:New Study Reveals Wide Variations in Depression Diagnoses among Ethnic Groups 2
... (Penicillin G) inhibits bacterial ... synthesis. Streptomycin belongs to ... inhibits bacterial growth by ... is used for prevention ...
...
Contains 10,000 units of penicillin (base), 10,000 g of streptomycin (base), and 25 g of amphotericin B/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and amphotericin B as Fungizone ...
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
Medicine Products: